Skip to main content

Table 1 Association and performance evaluation of DC-AD, DC-FTD, DC-DLB, and DC-other of each assessment section in predicting the corresponding “gold-standard” diagnosis

From: Transcranial magnetic stimulation and amyloid markers in mild cognitive impairment: impact on diagnostic confidence and diagnostic accuracy

Assessment steps

AUC (95%CI)

OR (95%CI)

p values*

Diagnosis of MCI-AD

 1. Clinical work-up

0.706 (0.637–0.775)

1.04 (1.02–1.05)

–

 2. Clinical work-up PLUS TMS

0.879 (0.809–0.950)

1.07 (1.05–1.10)

1 vs. 2, p < 0.001

 3. Clinical work-up PLUS amyloid markers

0.981 (0.953–1)

1.14 (1.09–1.22)

1 vs. 3, p < 0.001; 2 vs. 3, p < 0.010

 4. Clinical work-up PLUS TMS PLUS amyloid markers

0.975 (0.946–1)

1.10 (1.07–1.16)

4 vs. 1, p < 0.001; 4 vs. 2, p < 0.001

 5. Clinical work-up PLUS amyloid markers PLUS TMS

0.995 (0.986–1)

1.15 (1.09–1.38)

5 vs. 1, p < 0.001; 5 vs. 2, p < 0.001

Diagnosis of MCI-FTD

 1. Clinical work-up

0.796 (0.728–0.864)

1.05 (1.03–1.06)

–

 2. Clinical work-up PLUS TMS

0.913 (0.831–0.995)

1.08 (1.06–1.12)

1 vs. 2, p = 0.032

 3. Clinical work-up PLUS amyloid markers

0.910 (0.840–0.979)

1.07 (1.05–1.10)

3 vs. 1, p = 0.022

 4. Clinical work-up PLUS TMS PLUS amyloid markers

0.940 (0.868–1)

1.10 (1.06–1.16)

4 vs. 1, p = 0.005

 5. Clinical work-up PLUS amyloid markers PLUS TMS

0.910 (0.840–0.979)

1.10 (1.07–1.14)

5 vs. 1, p = 0.022

Diagnosis of MCI-DLB

 1. Clinical work-up

0.946 (0.907–0.946)

1.08 (1.06–1.11)

–

 2. Clinical work-up PLUS TMS

0.925 (0.836–1)

1.07 (1.04–1.10)

–

 3. Clinical work-up PLUS amyloid markers

0.983 (0.951–1)

1.08 (1.04–1.16)

–

 4. Clinical work-up PLUS TMS PLUS amyloid markers

0.925 (0.836–1)

1.07 (1.05–1.11)

–

 5. Clinical work-up PLUS amyloid markers PLUS TMS

0.998 (0.991–1)

1.33 (1.06–1.50)

–

Diagnosis of MCI-other

 1. Clinical work-up

0.752 (0.652–0.848)

1.04 (1.02–1.06)

–

 2. Clinical work-up PLUS TMS

0.889 (0.772–1)

1.08 (1.05–1.12)

–

 3. Clinical work-up PLUS amyloid markers

0.844 (0.729–0.959)

1.06 (1.04–1.08)

–

 4. Clinical work-up PLUS TMS PLUS amyloid markers

0.986 (0.965–1)

1.09 (1.06–1.15)

4 vs. 1, p < 0.001

 5. Clinical work-up PLUS amyloid markers PLUS TMS

0.957 (0.895–1)

1.09 (1.06–1.13)

5 vs. 1, p < 0.001

  1. Association was evaluated by odds ratio (OR) of logistic regression models; the performance was evaluated through AUC values of the receiver operating characteristic (ROC) curves
  2. DC diagnostic confidence, MCI-AD mild cognitive impairment due to Alzheimer disease, MCI-FTD mild cognitive impairment due to frontotemporal dementia, MCI-DLB mild cognitive impairment due to dementia with Lewy bodies, MCI-other mild cognitive impairment due to other conditions, AUC area under the curve, CI confidence interval, TMS transcranial magnetic stimulation
  3. *AUC comparisons: p value of significantly different AUC
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193